Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Emerald Clinical Trials Rebrands from George Clinical

George Clinical, a leading clinical research organization (CRO) operating worldwide, is pleased to announce it has rebranded to become Emerald Clinical Trials. This strategic name change underscores the company's well-established position as a...

PBZ OTC, the First New Topical Antihistamine in 50 Years, Unveiled by Kingsway Pharmaceuticals at Target Stores Nationwide

After 50 years, a new era in itch relief has arrived. PBZ OTC Pyribenzamine Antihistamine Cream, the first new topical antihistamine in half a century, is set to launch in April at Target stores across the United States. Powered by the trusted...

Glenmark Pharmaceuticals Launches Vancomycin Hydrochloride for Injection in the U.S

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch1 of Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial). Glenmark's Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25...

IRBM Expands Functional Genomics Platform for Early Drug Discovery

IRBM, an integrated Contract Research Organization (CRO) specializing in preclinical drug discovery, has established a comprehensive Functional Genomics Platform to support genetic target identification and validation, and generation of...

Cognito Therapeutics Presents Spectris™ Data on Brain Structural Maintenance in Alzheimer’s at AD/PD™ 2025

Cognito Therapeutics, a pioneering neurotechnology company developing disease-modifying therapies for neurodegenerative diseases, today announced new data from its OVERTURE feasibility trial at the AD/PD™ 2025. The results showed that Spectris™,...

PeptiGrowth Inc. Launches Novel Synthetic KGF Alternative Peptide (FGFR2b Agonist)

PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Junichiro Ishizuka) has successfully developed a novel synthetic peptide called "KGF alternative- peptide (FGFR2b agonist)" which is functionally equivalent to recombinant keratinocyte...

Hanmi Pharmaceutical Launches 'Aditams' in Mexico, Expanding into Latin America

Hanmi Pharmaceutical's combination therapy for Obstructive Prostatic Growth (OPG) caused by Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED), Gugutams, is entering the Mexican market under the local brand name "Aditams." Hanmi...

ELIQUENT Life Sciences Acquires Truliant Consulting, Expanding Pharmacovigilance Platform

ELIQUENT Life Sciences (ELIQUENT), a global regulatory, quality, and safety consulting firm, today announced the acquisition of Truliant Consulting (Truliant), a leading pharmacovigilance, risk management, and regulatory compliance advisory firm....

Fast Company recognizes Bruin Biometrics as a top 10 innovative medical device maker

Bruin Biometrics LLC, a medical technology platform company that provides digital solutions for pressure injury prevention and management to health systems in the U.S. and U.K., announced it has been named by Fast Company as one of the World's 10...

Medline to launch a synthetic ligament augmentation implant.

Attendees at this year's American College of Foot and Ankle Surgeons Annual Meeting in Phoenix, Ariz. will be the first to see Medline UNITE's new Synthetic Ligament Augmentation implant. The intelligently designed solution provides the next...

Pint Pharma secures ANVISA approval for BESREMi® to treat Polycythemia Vera

Pint Pharma and PharmaEssentia announced that ANVISA (Brazilian Health Regulatory Agency) has approved BESREMi® (ropeginterferon alfa-2b) for the treatment of adult patients with Polycythemia Vera (PV). Polycythemia Vera (PV) is a rare, chronic,...

Secretome Therapeutics' STM-01, a neonatal cardiac progenitor cell therapy for HFpEF, receives FDA Fast Track designation

Secretome Therapeutics, a pioneering company in the field of regenerative medicine, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to STM-01, the company’s neonatal cardiac progenitor cell (nCPC)...

Developing innovative production technology for the commercialization of 3D cell products, PHC and Cyfuse collaborate

PHC Corporation a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Kyoko Deguchi), and Cyfuse Biomedical K.K. announce the successful development of a new production technology(*1) for the commercialization of...

Marking a new era of uncovering the potential of NAD+ with precision science, ChromaDex evolves into Niagen Bioscience

Niagen Bioscience, Inc. the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today confirmed it has changed its corporate name to Niagen Bioscience, Inc. (“Niagen Bioscience” or the...

Medit introduces SmartX, a new All-on-X solution for digital dentistry

Medit a global leader in digital dentistry, has launched its latest All-on-X solution, Medit SmartX. This innovative solution empowers implant clinicians to fully leverage the potential of the digital ecosystem. Medit SmartX integrates with a wide...

Actinium Pharmaceuticals publishes Actimab-A + CLAG-M trial results for relapsed/refractory AML in Leukemia

Actinium Pharmaceuticals, Inc. a pioneer in the development of targeted radiotherapies, announced that results from the clinical trial evaluating Actimab-A in combination with the chemotherapy CLAG-M in patients with relapsed/refractory acute...

Applications Are Being Accepted by the Vilcek Foundation from Immigrants Working in Biomedical Science

Vilcek Foundation Prizes for Creative Promise in Biomedical Science are being accepted now through June 9, 2025. These $50,000 prizes are given each year to three early- to mid-career immigrant scientists living in the United States who have made...

Key Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial Reported by Blue Earth Therapeutics

Blue Earth Therapeutics today announced further promising developments for its radiohybrid lutetium labelled, PSMA targeted, investigational radioligand therapy. Radiation dosimetry and pharmacokinetic data from the 13 metastatic castrate...

Fzata secures a clinical trial agreement for FZ002, targeting C. difficile treatment.

Fzata, Inc. announces the execution of a clinical trial agreement with the National Institutes of Health (NIH) to sponsor a Phase 1 clinical trial of FZ002 for C. difficile treatment. Oral FZ002 is a live yeast genetically modified to express a...

Peer-Reviewed Study in Obesity Pillars Further Substantiates Cardiovascular Safety Profile of CONTRAVE®/MYSIMBA, according to Currax Pharmaceuticals

Currax Pharmaceuticals LLC a specialty pharmaceutical company and manufacturer of the #1 branded oral weight loss medication CONTRAVE® (naltrexone HCl/bupropion HCl), announced the publication of its Cardiovascular Health Outcomes Analysis (HOA)...